Dr. Steven Gore on Potential Negative Effects of Further Research into Azanucleoside Combinations
October 28th 2015Steven D. Gore, MD, director of Hematologic Malignancies at Yale Cancer Center, talks about the risk of constantly testing azanucleoside combinations without significant results. Gore says that testing azanucleoside combinations that are not well planned may cause the medical community to overlook an effective combination due to fatigue of constant testing.
Watch
Dr. Clifford A. Hudis on Why Resistance to HER-2 Therapies Needs to be Further Researched
October 27th 2015Clifford A. Hudis, MD, FACP, Vice President for Government Relations and Chief Advocacy Officer, Chief, Breast Medicine Service at Memorial Sloan Kettering Cancer Center, talks about the vague understanding medical professional currently have of HER-2 breast cancer and its resistance to certain therapies.
Watch
Dr. Julie Gralow on the Importance of Genetic Testing for Breast Cancer
October 26th 2015Julie Gralow, MD, Professor, Medical Oncology Division, University of Washington School of Medicine, talks about the importance of women knowing which genetic tests they�ve previously had done for breast cancer.
Watch